BioCentury | Feb 8, 2019
Company News

Sanofi seeking partner to develop Oxford BioMedica's ophthalmology gene therapies

...are StarGen (SAR422459), a LentiVector-based gene therapy expressing a corrected version of ABCA4, and UshStat (SAR 421869...
...I/II proof-of-concept study for StarGen to treat Stargardt disease, but will not continue to develop UshStat...
...Oxford BioMedica plc (LSE:OXB), Oxford, U.K. Sanofi (Euronext:SAN; NASDAQ:SNY), Paris, France Business: Ophthalmology Shannon Lehnbeuter StarGen (SAR422459) UshStat (SAR 421869) Oxford...
BioCentury | Jun 15, 2015
Emerging Company Profile

Freshening the gene pool

...compound is in Phase III testing for RPE65-mediated retinitis pigmentosa and LCA. Oxford BioMedica plc's UshStat...
BioCentury | Feb 24, 2014
Company News

Oxford BioMedica, Sanofi deal

...companies amended an April 2009 deal to grant Sanofi broadened worldwide rights to StarGen and UshStat...
...BioMedica said it is eligible for development and commercialization milestones, plus royalties, for StarGen and UshStat...
...worldwide license to develop and commercialize four preclinical compounds to treat ocular diseases, including StarGen, UshStat...
BioCentury | Oct 28, 2013
Clinical News

StarGen: Phase I/IIa ongoing

...agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen and UshStat...
...the U.S. and EU. Sanofi also exercised its option to acquire exclusive, worldwide rights to UshStat...
...1B. The trial is evaluating 3 single doses of UshStat in up to 18 patients. UshStat...
BioCentury | Oct 28, 2013
Clinical News

UshStat: Phase I/IIa ongoing

...agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen and UshStat...
...the U.S. and EU. Sanofi also exercised its option to acquire exclusive, worldwide rights to UshStat...
...1B. The trial is evaluating 3 single doses of UshStat in up to 18 patients. UshStat...
BioCentury | Oct 28, 2013
Clinical News

RetinoStat: Phase I ongoing

...agreed to allow the company to resume enrollment in Phase I/IIa trials of StarGen and UshStat...
...the U.S. and EU. Sanofi also exercised its option to acquire exclusive, worldwide rights to UshStat...
...1B. The trial is evaluating 3 single doses of UshStat in up to 18 patients. UshStat...
BioCentury | Jun 10, 2013
Clinical News

RetinoStat: Phase I suspended enrollment

...enrollment in a Phase I trial of RetinoStat and Phase I/IIa trials of StarGen and UshStat...
...the U.S. and EU. Sanofi also exercised its option to acquire exclusive, worldwide rights to UshStat...
...1B. The trial is evaluating 3 single doses of UshStat in up to 18 patients. UshStat...
BioCentury | Jun 10, 2013
Clinical News

StarGen: Phase I/IIa suspended enrollment

...enrollment in a Phase I trial of RetinoStat and Phase I/IIa trials of StarGen and UshStat...
...the U.S. and EU. Sanofi also exercised its option to acquire exclusive, worldwide rights to UshStat...
...1B. The trial is evaluating 3 single doses of UshStat in up to 18 patients. UshStat...
BioCentury | Jun 10, 2013
Clinical News

UshStat: Phase I/IIa suspended enrollment

...enrollment in a Phase I trial of RetinoStat and Phase I/IIa trials of StarGen and UshStat...
...the U.S. and EU. Sanofi also exercised its option to acquire exclusive, worldwide rights to UshStat...
...1B. The trial is evaluating 3 single doses of UshStat in up to 18 patients. UshStat...
BioCentury | Dec 10, 2012
Clinical News

UshStat: Phase I/IIa ongoing

...continuation to the second dose cohort in an open-label, dose-escalation, U.S. Phase I/IIa trial of UshStat...
...events. The trial is evaluating 3 single doses of UshStat in up to 18 patients. UshStat...
...Sanofi exercised its option under an April 2009 deal to acquire exclusive, worldwide rights to UshStat...
Items per page:
1 - 10 of 13